Economic evaluation of projects involving changes in mortality risk conventionally assumes that lives are statistical, i.e., that risks and policy-induced changes in risk are small and similar among a population. In reality, baseline mortality risks and policy-induced changes in risk often...

COVID-19 führt seit zwei Jahren weltweit zu schweren Erkrankungen, Todesfällen und drastischen Gegenmaßnahmen. Mit sehr schnell entwickelten Impfstoffen haben sich viele Menschen in Deutschland impfen lassen. Zur weiteren Erhöhung der Impfquote wird über eine zuvor ausgeschlossene...

Cost-benefit analysis (CBA), as a distinctive tool for public investment projects evaluation laying in the portfolio of the governmental authorities, strives to replicate the market in establishing economic standards for the measurement of their success, while the government’s actions are in...

The standard literature on the value of life relies on Yaari’s (1965) model, which includes an implicit assumption of risk neutrality with respect to life duration. To overpass this limitation, we extend the theory to a simple variety of nonadditively separable preferences. The enlargement we...

To analyze rubella vaccination strategies we calculated benefits and costs of prevention of rubella. With no vaccination, lifetime expenditures for congenital rubella syndrome in offspring of females are greater than $35 per female (present value). Expenditures for acute rubella are less than...

Using a dynamic model of the control of an infectious disease, we derive the conditions under which eradication will be optimal. When eradication is feasible, the optimal program requires either a low vaccination rate or eradication. A high vaccination rate is never optimal. Under special...